Completed PHASE3 INTERVENTIONAL 2-arm NCT00947752

Safety of New Formulation of Glatiramer Acetate (Song)

An Open-Label, Multicenter, Randomized Study Evaluating the Tolerability and Safety of Two Formulations of Glatiramer Acetate (GA) for Subcutaneous Injection

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Conditions Relapsing Remitting Multiple Sclerosis

Interventions Experimental Glatiramer Acetate Glatiramer Acetate

Updated 10 times since 2017 Last updated: Feb 2, 2017 Started: Jul 31, 2009 Primary completion: Sep 30, 2009 Completion: Nov 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Relapsing Remitting Multiple Sclerosis, this trial is completed. The trial is conducted by Teva Branded Pharmaceutical Products R&D, Inc. and has accumulated 10 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2023 — Jul 2024 [monthly]

Completed PHASE3
Dec 2022 — Jan 2023 [monthly]

Completed PHASE3
Jan 2022 — Dec 2022 [monthly]

Completed PHASE3

▶ Show 5 earlier versions

Dec 2021 — Jan 2022 [monthly]

Completed PHASE3
Jan 2021 — Dec 2021 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jul 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Teva Branded Pharmaceutical Products R&D, Inc.

Data source: Teva Branded Pharmaceutical Products R&D, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.